Phase I Study of Cisplatin Plus OSI-7904L in Patients With Solid Tumors

Phase I Study of OSI-7904L in Combination With Cisplatin in Patients With Advanced Solid Tumors

This is a Phase I, open-label, dose escalation, study of the combination of cisplatin and OSI-7904L given on Day 1 every 21 days in patient who have advanced solid tumors.

Inclusion Criteria:

• 18 years of age or older
• Advanced and/or metastatic solid tumor for which no effective therapy is available
• ECOG performance status 0-2
• Adequate bone marrow, hepatic and renal function

Exclusion Criteria:

• Patients with active or uncontrolled infections
• Neurotoxicity >= Grade 2
• Symptomatic brain metastases which are not stable